TELA Bio, Inc.
Qualité des données : 100%
TELA
Nasdaq
Manufacturing
Measuring & Analyzing Instruments
0,57 €
▼
0,03 €
(-4,73%)
Cap. Boursière: 26,52 M
Prix
0,59 €
Cap. Boursière
26,52 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Revenue grew 28,48% annually over 5 years — strong growth
Debt/Equity of 26,65 — high leverage
Negative free cash flow of -28,67 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 12,64%
Capital efficient — spends only 0,56% of revenue on capex
Croissance
Revenue Growth (5Y)
28,48%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)15,84%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-723,04%
En dessous de la moyenne du secteur (-53,47%)
ROIC-57,29%
Net Margin-48,37%
Op. Margin-42,05%
Sécurité
Debt / Equity
26,65
Au-dessus de la moyenne du secteur (0,30)
Current Ratio3,30
Interest Coverage-6,44
Valorisation
PE (TTM)
-0,68
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio17,03
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -0,7 | -1,5 |
| P/B | 17,0 | 1,6 |
| ROE % | -723,0 | -53,5 |
| Net Margin % | -48,4 | -41,5 |
| Rev Growth 5Y % | 28,5 | 1,8 |
| D/E | 26,7 | 0,3 |
Objectif de Cours des Analystes
5 analystes
Buy
Actuel
0,57 €
Objectif
2,25 €
1,00 €
2,00 €
3,25 €
Prévisions
P/E Prévisionnel
-1,01
BPA Prévisionnel
-0,56 €
CA Est.
97,24 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-0,56 €
-0,76 € – -0,43 €
|
97,24 M | 5 |
| FY2026 |
-0,67 €
-0,88 € – -0,57 €
|
86,75 M | 5 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,18 €
-0,22 € – -0,14 €
|
21,04 M | 5 |
| 2026 Q1 |
-0,19 €
-0,24 € – -0,14 €
|
18,50 M | 5 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,18 € | -0,17 € | +6,6% |
| Q32025 | -0,20 € | -0,19 € | +5,0% |
| Q22025 | -0,19 € | -0,22 € | -18,9% |
| Q12025 | -0,21 € | -0,25 € | -20,5% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 15,84% | Revenue Growth (3Y) | 17,19% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 28,48% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 80,28 M | Net Income (TTM) | -38,83 M |
| ROE | -723,04% | ROA | -60,15% |
| Gross Margin | 67,69% | Operating Margin | -42,05% |
| Net Margin | -48,37% | Free Cash Flow (TTM) | -28,67 M |
| ROIC | -57,29% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 26,65 | Current Ratio | 3,30 |
| Interest Coverage | -6,44 | Asset Turnover | 1,24 |
| Working Capital | 39,07 M | Tangible Book Value | 103 000 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,68 | Forward P/E | N/A |
| P/B Ratio | 17,03 | P/S Ratio | 0,33 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -108,11% | ||
| Market Cap | 26,52 M | Enterprise Value | 38,30 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,83 | Revenue / Share | 1,79 |
| FCF / Share | -0,64 | OCF / Share | -0,63 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,56% | FCF Conversion | 73,83% |
| SBC-Adj. FCF | -32,73 M | Growth Momentum | -12,64 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 80,28 M | 69,30 M | 58,45 M | 41,42 M | 29,46 M |
| Net Income | -38,83 M | -37,84 M | -46,66 M | -44,30 M | -33,28 M |
| EPS (Diluted) | -0,83 | -1,33 | -2,04 | -2,72 | -2,30 |
| Gross Profit | 54,34 M | 46,49 M | 40,11 M | 27,04 M | 18,81 M |
| Operating Income | -33,76 M | -34,12 M | -44,08 M | -39,01 M | -29,45 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 9,22 M | 8,81 M | 9,62 M | 8,94 M | 6,74 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 5,25 M | 5,29 M | 5,22 M | 4,05 M | 3,60 M |
| Income Tax | 230 000,0 | -144 000,0 | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 81,42 M | 86,57 M | 78,05 M | 67,86 M | 62,54 M |
| Total Liabilities | 75,11 M | 58,11 M | 59,17 M | 53,55 M | 42,45 M |
| Shareholders' Equity | 6,31 M | 28,46 M | 18,88 M | 14,31 M | 20,10 M |
| Total Debt | 55,65 M | 41,12 M | 40,52 M | 39,92 M | 31,49 M |
| Cash & Equivalents | 50,85 M | 52,67 M | 46,73 M | 42,02 M | 43,93 M |
| Current Assets | 75,58 M | 78,07 M | 71,73 M | 62,45 M | 59,06 M |
| Current Liabilities | 17,98 M | 15,60 M | 16,97 M | 12,40 M | 10,58 M |
{"event":"ticker_viewed","properties":{"ticker":"TELA","listing_kind":"stock","pathname":"/stocks/tela","exchange":"Nasdaq","country":"US"}}